1. Reduced Intensity Versus Myeloablative Conditioning Allogeneic HCT for Relapsed/Refractory Lymphoma: Applying Refined Disease Risk Index (DRI) to Improve Survival 
Aleksandr Lazaryan, MD MPH PhD, Veronika Bachanova, MD, PhD, Qing Cao, MS, Brian Lee McClune, DO, Mukta Arora, MD, MS, Rohtesh S. Mehta, MD MPH, John E. Wagner, MD, Claudio G. Brunstein, MD, PhD, Daniel J. Weisdorf, MD, Nelli Bejanyan, MD 
Biology of Blood and Marrow Transplantation 
Volume 22, Issue 3, Pages S225-S226 (March 2016)
DOI: /j.bbmt
Copyright © Terms and Conditions

2. Figure 1
2-yr PFS as predicted by DRI (A); and Stratified 2-yr OS for RIC vs. MA alloHCT in patients with intermediate risk DRI (B).
Biology of Blood and Marrow Transplantation  , S225-S226DOI: ( /j.bbmt )
Copyright © Terms and Conditions